{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:22:35Z","timestamp":1791296555105,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1038\/mp.2017.4","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T15:09:12Z","timestamp":1487689752000},"page":"1594-1603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice"],"prefix":"10.1038","volume":"22","author":[{"given":"A","family":"Busquets-Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Soria-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Redon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Mackenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Vall\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Chaouloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Varilh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P-V","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Marsicano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,21]]},"reference":[{"key":"BFmp20174_CR1","unstructured":"United Nations Office on Drugs and Crime. World Drug Report 2014."},{"key":"BFmp20174_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40429-014-0018-7","volume":"1","author":"ST Wilkinson","year":"2014","unstructured":"Wilkinson ST, Radhakrishnan R, D'Souza DC . Impact of Cannabis use on the development of psychotic disorders. Curr Addict Rep 2014; 1: 115\u2013128.","journal-title":"Curr Addict Rep"},{"key":"BFmp20174_CR3","first-page":"5","volume":"22","author":"R Radhakrishnan","year":"2014","unstructured":"Radhakrishnan R, Wilkinson ST, D'Souza DC . Gone to pot\u2014a review of the association between Cannabis and psychosis. Front Psychiatry 2014; 22: 5\u201354.","journal-title":"Front Psychiatry"},{"key":"BFmp20174_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(07)61162-3","volume":"370","author":"TH Moore","year":"2007","unstructured":"Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319\u2013328.","journal-title":"Lancet"},{"key":"BFmp20174_CR5","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s12035-016-9697-5","volume":"54","author":"M Fakhoury","year":"2016","unstructured":"Fakhoury M . Role of the endocannabinoid system in the pathophysiology of schizophrenia. Mol Neurobiol 2016; 54: 768\u2013778.","journal-title":"Mol Neurobiol"},{"key":"BFmp20174_CR6","first-page":"00643","volume":"3223","author":"T Rubino","year":"2015","unstructured":"Rubino T, Parolaro D . The impact of exposure to cannabinoids in adolescence: insights from animal models. Biol Psychiatry 2015; 3223: 00643\u201300645.","journal-title":"Biol Psychiatry"},{"key":"BFmp20174_CR7","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/09595230310001613976","volume":"22","author":"B Green","year":"2003","unstructured":"Green B, Kavanagh D, Young R . Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev 2003; 22: 453\u2013460.","journal-title":"Drug Alcohol Rev"},{"key":"BFmp20174_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00406-009-0024-2","volume":"259","author":"DC D'Souza","year":"2009","unstructured":"D'Souza DC, Sewell RA, Ranganathan M . Cannabis and psychosis\/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 2009; 259: 413\u2013431.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"BFmp20174_CR9","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1369-1600.2008.00106.x","volume":"13","author":"FM Leweke","year":"2008","unstructured":"Leweke FM, Koethe D . Cannabis and psychiatric disorders: it is not only addiction. Addict Biol 2008; 13: 264\u2013275.","journal-title":"Addict Biol"},{"key":"BFmp20174_CR10","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","volume":"29","author":"DC D\u2019Souza","year":"2004","unstructured":"D\u2019Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004; 29: 1558\u20131572.","journal-title":"Neuropsychopharmacology"},{"key":"BFmp20174_CR11","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1017\/S0033291709005522","volume":"39","author":"PD Morrison","year":"2009","unstructured":"Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF et al. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 2009; 39: 1607\u20131616.","journal-title":"Psychol Med"},{"key":"BFmp20174_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00213-013-3188-4","volume":"228","author":"M Spaderna","year":"2013","unstructured":"Spaderna M, Addy PH, D'Souza DC . Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl) 2013; 228: 525\u2013540.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFmp20174_CR13","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2165\/00023210-200418130-00005","volume":"18","author":"FM Leweke","year":"2004","unstructured":"Leweke FM, Gerth CW, Klosterk\u00f6tter J . Cannabis-associated psychosis: current status of research. CNS Drugs 2004; 18: 895\u2013910.","journal-title":"CNS Drugs"},{"key":"BFmp20174_CR14","first-page":"CD009831","volume":"1","author":"M Dold","year":"2015","unstructured":"Dold M, Samara MT, Li C, Tardy M, Leucht S . Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database Syst Rev 2015; 1: CD009831.","journal-title":"Cochrane Database Syst Rev"},{"key":"BFmp20174_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-3-642-25761-2_2","volume":"212","author":"N Ginovart","year":"2012","unstructured":"Ginovart N, Kapur S . Role of dopamine D(2) receptors for antipsychotic activity. Handb Exp Pharmacol 2012; 212: 27\u201352.","journal-title":"Handb Exp Pharmacol"},{"key":"BFmp20174_CR16","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1192\/bjp.bp.109.066217","volume":"196","author":"NA Crossley","year":"2010","unstructured":"Crossley NA, Constante M, McGuire P, Power P . Efficacy of atypical vs. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 2010; 196: 434\u2013439.","journal-title":"Br J Psychiatry"},{"key":"BFmp20174_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4088\/PCC.v02n0601","volume":"2","author":"RJ Leo","year":"2000","unstructured":"Leo RJ, Regno PD . Atypical antipsychotic use in the treatment of psychosis in primary care. Prim Care Companion J Clin Psychiatry 2000; 2: 194\u2013204.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"BFmp20174_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2125.2012.04418.x","volume":"77","author":"M Lader","year":"2014","unstructured":"Lader M . Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol 2014; 77: 295\u2013301.","journal-title":"Br J Clin Pharmacol"},{"key":"BFmp20174_CR19","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.4088\/JCP.10r06264yel","volume":"71","author":"JM Kane","year":"2010","unstructured":"Kane JM, Correll CU . Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 2010; 71: 1115\u20131124.","journal-title":"J Clin Psychiatry"},{"key":"BFmp20174_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1517\/17460441.2014.966680","volume":"10","author":"R Wyrofsky","year":"2015","unstructured":"Wyrofsky R, McGonigle P, Van Bockstaele EJ . Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease. Expert Opin Drug Discov 2015; 10: 17\u201336.","journal-title":"Expert Opin Drug Discov"},{"key":"BFmp20174_CR21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.biopsych.2015.11.018","volume":"79","author":"FM Leweke","year":"2016","unstructured":"Leweke FM, Mueller JK, Lange B, Rohleder C . Therapeutic potential of Cannabinoids in Psychosis. Biol Psychiatry 2016; 79: 604\u2013612.","journal-title":"Biol Psychiatry"},{"key":"BFmp20174_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3109\/15622970801908047","volume":"11","author":"P Roser","year":"2010","unstructured":"Roser P, Vollenweider FX, Kawohl W . Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. World J Biol Psychiatry 2010; 11: 208\u2013219.","journal-title":"World J Biol Psychiatry"},{"key":"BFmp20174_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/00008877-200006000-00008","volume":"11","author":"B Scatton","year":"2000","unstructured":"Scatton B, Sanger DJ . Pharmacological and molecular targets in the search for novel antipsychotics. Behav Pharmacol 2000; 11: 243\u2013256.","journal-title":"Behav Pharmacol"},{"key":"BFmp20174_CR24","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.2174\/138161212802884744","volume":"18","author":"E Zamberletti","year":"2012","unstructured":"Zamberletti E, Rubino T, Parolaro D . The endocannabinoid system and schizophrenia: integration of evidence. Curr Pharmaceut Des 2012; 18: 4980\u20134990.","journal-title":"Curr Pharmaceut Des"},{"key":"BFmp20174_CR25","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","volume":"370","author":"R Christensen","year":"2007","unstructured":"Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A . Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370: 1706\u20131713.","journal-title":"Lancet"},{"key":"BFmp20174_CR26","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1001\/jama.299.13.1601","volume":"99","author":"JS Rumsfeld","year":"2008","unstructured":"Rumsfeld JS, Nallamothu BK . The hope and fear of rimonabant. JAMA 2008; 99: 1601\u20131602.","journal-title":"JAMA"},{"key":"BFmp20174_CR27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1126\/science.1243985","volume":"343","author":"M Vallee","year":"2014","unstructured":"Vallee M, Vitiello S, Bellocchio L, Hebert-Chatelain E, Monlezun S, Martin-Garcia E et al. Pregnenolone can protect the brain from cannabis intoxication. Science 2014; 343: 94\u201398.","journal-title":"Science"},{"key":"BFmp20174_CR28","unstructured":"Piazza PV, Vall\u00e9e M, Marsicano G, Felpin FX, Bellocchio L, Cota D et al Antagonists of CB1 receptor. Patent 2012. Publication number: WO2012\/160006.."},{"key":"BFmp20174_CR29","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/schbul\/sbp050","volume":"35","author":"M McDannald","year":"2009","unstructured":"McDannald M, Schoenbaum G . Toward a model of impaired reality testing in rats. Schizophr Bull 2009; 35: 664\u2013667.","journal-title":"Schizophr Bull"},{"key":"BFmp20174_CR30","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.biopsych.2011.06.014","volume":"70","author":"MA McDannald","year":"2011","unstructured":"McDannald MA, Whitt JP, Calhoon GG, Piantadosi PT, Karlsson RM, O'Donnell P et al. Impaired reality testing in an animal model of schizophrenia. Biol Psychiatry 2011; 70: 1122\u20131126.","journal-title":"Biol Psychiatry"},{"key":"BFmp20174_CR31","doi-asserted-by":"publisher","first-page":"e0146376","DOI":"10.1371\/journal.pone.0146376","volume":"11","author":"HJ Kim","year":"2016","unstructured":"Kim HJ, Koh HY . Impaired reality testing in mice lacking phospholipase C\u03b21: observed by persistent representation-mediated taste aversion. PLoS ONE 2016; 11: e0146376.","journal-title":"PLoS ONE"},{"key":"BFmp20174_CR32","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.neuron.2015.08.035","volume":"88","author":"E Soria-G\u00f3mez","year":"2015","unstructured":"Soria-G\u00f3mez E, Busquets-Garcia A, Hu F, Mehidi A, Cannich A, Roux L et al. Habenular CB1 receptors control the expression of aversive memories. Neuron 2015; 88: 306\u2013313.","journal-title":"Neuron"},{"key":"BFmp20174_CR33","unstructured":"Paxinos G, Franklin KBJ . The Mouse Brain in Stereotaxic Coordinates, 4th edn. Academic Press: San Diego, 2001."},{"key":"BFmp20174_CR34","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.cell.2012.01.037","volume":"148","author":"J Han","year":"2012","unstructured":"Han J, Kesner P, Metna-Laurent M, Duan T, Xu L, Georges F et al. Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 2012; 148: 1039\u20131050.","journal-title":"Cell"},{"key":"BFmp20174_CR35","unstructured":"American Psychiatric Association. DSM, 4th edn. APS: Washington, DC, 2000."},{"key":"BFmp20174_CR36","unstructured":"American Psychiatric Association. DSM, 5th edn. APS: Washington, DC, 2013."},{"key":"BFmp20174_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0149-7634(01)00041-0","volume":"26","author":"R Lalonde","year":"2002","unstructured":"Lalonde R . The neurobiological basis of spontaneous alternation. Neurosci Biobehav Rev 2002; 26: 91\u2013104.","journal-title":"Neurosci Biobehav Rev"},{"key":"BFmp20174_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/(SICI)1098-1063(1999)9:2<118::AID-HIPO4>3.0.CO;2-8","volume":"9","author":"RJ Steele","year":"1999","unstructured":"Steele RJ, Morris RG . Delay-dependent impairment of a matching-to-place task with chronic and intrahippocampal infusion of the NMDA-antagonist D-AP5. Hippocampus 1999; 9: 118\u2013136.","journal-title":"Hippocampus"},{"key":"BFmp20174_CR39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00213-002-1240-x","volume":"165","author":"RS Martin","year":"2003","unstructured":"Martin RS, Secchi RL, Sung E, Lemaire M, Bonhaus DW, Hedley LR et al. Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in rat. Psychopharmacology (Berl) 2003; 165: 128\u2013135.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFmp20174_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2013.08.002","volume":"150","author":"R Tandon","year":"2013","unstructured":"Tandon R . Definition of psychotic disorders in the DSM-5 too radical, too conservative, or just right!. Schizophr Res 2013; 150: 1\u20132.","journal-title":"Schizophr Res"},{"key":"BFmp20174_CR41","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/j.1476-5381.2011.01386.x","volume":"164","author":"CA Jones","year":"2011","unstructured":"Jones CA, Watson DJ, Fone KC . Animal models of schizophrenia. Br J Pharmacol 2011; 164: 1162\u20131194.","journal-title":"Br J Pharmacol"},{"key":"BFmp20174_CR42","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0149-7634(03)00035-6","volume":"27","author":"AH Wong","year":"2003","unstructured":"Wong AH, Van Tol HH . Schizophrenia: from phenomenology to neurobiology. Neurosci Biobehav Rev 2003; 27: 269\u201330.","journal-title":"Neurosci Biobehav Rev"},{"key":"BFmp20174_CR43","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1080\/j.1440-1614.2005.01626.x","volume":"105","author":"M van den Buuse","year":"2005","unstructured":"van den Buuse M, Garner B, Gogos A, Kusljic S . Importance of animal models in schizophrenia research. Aust NZ J Psychiatry 2005; 105: 550\u2013557.","journal-title":"Aust NZ J Psychiatry"},{"key":"BFmp20174_CR44","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0014-2999(00)00044-3","volume":"391","author":"MC Sa\u00f1udo-Pe\u00f1a","year":"2000","unstructured":"Sa\u00f1udo-Pe\u00f1a MC, Romero J, Seale GE, Fernandez-Ruiz JJ, Walker JM . Activational role of cannabinoids on movement. Eur J Pharmacol 2000; 391: 269\u2013274.","journal-title":"Eur J Pharmacol"},{"key":"BFmp20174_CR45","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1017\/S1461145709990605","volume":"13","author":"LE Long","year":"2010","unstructured":"Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T . A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol inC57BL\/6JArc mice. Int J Neuropsychopharmacol 2010; 13: 861\u2013876.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFmp20174_CR46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.31887\/DCNS.2015.17.1\/wgaebel","volume":"17","author":"W Gaebel","year":"2015","unstructured":"Gaebel W, Zielasek J . Focus on psychosis. Dialogues Clin Neurosci 2015; 17: 9\u201318.","journal-title":"Dialogues Clin Neurosci"},{"key":"BFmp20174_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nlm.2012.12.015","volume":"101","author":"DS Wheeler","year":"2013","unstructured":"Wheeler DS, Chang SE, Holland PC . Odor-mediated taste learning requires dorsal hippocampus, but not basolateral amygdala activity. Neurobiol Learn Mem 2013; 101: 1\u20137.","journal-title":"Neurobiol Learn Mem"},{"key":"BFmp20174_CR48","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/0091-3057(86)90156-5","volume":"25","author":"R Nemeth-Coslett","year":"1986","unstructured":"Nemeth-Coslett R, Henningfield JE, O\u2019Keeffe MK, Griffiths RR . Effects of marijuana smoking on subjective ratings and tobacco smoking. Pharmacol Biochem Behav 1986; 25: 659\u2013665.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFmp20174_CR49","doi-asserted-by":"publisher","first-page":"4723","DOI":"10.1007\/s00213-014-3630-2","volume":"231","author":"CC Hunault","year":"2014","unstructured":"Hunault CC, B\u00f6cker KB, Stellato RK, Kenemans JL, de Vries I, Meulenbelt J . Acute subjective effects after smoking joints containing up to 69 mg \u03949-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial. Psychopharmacology (Berl) 2014; 231: 4723\u20134733.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFmp20174_CR50","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.psychres.2013.10.029","volume":"215","author":"TV Lagerberg","year":"2014","unstructured":"Lagerberg TV, Kvitland LR, Aminoff SR, Aas M, Ringen PA, Andreassen OA et al. Indications of a dose-response relationship between cannabis use and age at onset in bipolar disorder. Psychiatry Res 2014; 215: 101\u2013104.","journal-title":"Psychiatry Res"},{"key":"BFmp20174_CR51","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/bmj.327.7407.165-a","volume":"327","author":"CH Aston","year":"2003","unstructured":"Aston CH . Comparing cannabis with tobacco: those who start taking cannabis young have the greatest problems. BMJ 2003; 327: 165.","journal-title":"BMJ"},{"key":"BFmp20174_CR52","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nn.3053","volume":"15","author":"G B\u00e9nard","year":"2012","unstructured":"B\u00e9nard G, Massa F, Puente N, Louren\u00e7o J, Bellocchio L, Soria-G\u00f3mez E et al. Mitochondrial CB1 receptors regulate neuronal energy metabolism. Nat Neurosci 2012; 15: 558\u2013564.","journal-title":"Nat Neurosci"},{"key":"BFmp20174_CR53","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.neuroscience.2011.04.017","volume":"191","author":"MS Ritsner","year":"2011","unstructured":"Ritsner MS . The clinical and therapeutic potentials of dehydroepiandrosterone and pregnenolone in schizophrenia. Neuroscience 2011; 191: 91\u2013100.","journal-title":"Neuroscience"},{"key":"BFmp20174_CR54","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.4088\/JCP.09m05031yel","volume":"71","author":"MS Ritsner","year":"2010","unstructured":"Ritsner MS, Gibel A, Shleifer T, Boguslavsky I, Zayed A, Maayan R et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry 2010; 71: 1351\u20131362.","journal-title":"J Clin Psychiatry"},{"key":"BFmp20174_CR55","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1007\/s00213-014-3673-4","volume":"231","author":"CE Marx","year":"2014","unstructured":"Marx CE, Lee J, Subramaniam M, Rapisarda A, Bautista DC, Chan E et al. Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. Psychopharmacology (Berl) 2014; 231: 3647\u20133662.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFmp20174_CR56","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.pnpbp.2004.05.017","volume":"28","author":"SV Kyosseva","year":"2004","unstructured":"Kyosseva SV . Differential expression of mitogen-activated protein kinases and immediate early genes fos and jun in thalamus in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 997\u20131006.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFmp20174_CR57","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1080\/14734220410029164","volume":"3","author":"SV Kyosseva","year":"2004","unstructured":"Kyosseva SV . The role of the extracellular signal-regulated kinase pathway in cerebellar abnormalities in schizophrenia. Cerebellum 2004; 3: 94\u201399.","journal-title":"Cerebellum"},{"key":"BFmp20174_CR58","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pharmthera.2009.06.001","volume":"124","author":"R Molteni","year":"2009","unstructured":"Molteni R, Calabrese F, Racagni G, Fumagalli F, Riva MA . Antipsychotic drug actions on gene modulation and signaling mechanisms. Pharmacol Ther 2009; 124: 74\u201385.","journal-title":"Pharmacol Ther"},{"key":"BFmp20174_CR59","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.neuron.2008.10.010","volume":"60","author":"MP Mattson","year":"2008","unstructured":"Mattson MP, Gleichmann M, Cheng A . Mitochondria in neuroplasticity and neurological disorders. Neuron 2008; 60: 748\u2013766.","journal-title":"Neuron"},{"key":"BFmp20174_CR60","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neubiorev.2014.11.005","volume":"48","author":"A Rajasekaran","year":"2015","unstructured":"Rajasekaran A, Venkatasubramanian G, Berk M, Debnath M . Mitochondrial dysfunction in schizophrenia: pathways, mechanisms and implications. Neurosci Biobehav Rev 2015; 48: 10\u201321.","journal-title":"Neurosci Biobehav Rev"},{"key":"BFmp20174_CR61","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00439-014-1491-8","volume":"134","author":"VF Gon\u00e7alves","year":"2015","unstructured":"Gon\u00e7alves VF, Andreazza AC, Kennedy JL . Mitochondrial dysfunction in schizophrenia: an evolutionary perspective. Hum Genet 2015; 134: 13\u201321.","journal-title":"Hum Genet"},{"key":"BFmp20174_CR62","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1371\/journal.pmed.0030327","volume":"3","author":"E Holmes","year":"2006","unstructured":"Holmes E, Tsang TM, Huang JT, Leweke FM, Koethe D, Gerth CW et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med 2006; 3: e327.","journal-title":"PLoS Med"},{"key":"BFmp20174_CR63","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.pnpbp.2013.07.020","volume":"52","author":"T Rubino","year":"2014","unstructured":"Rubino T, Parolaro D . Cannabis abuse in adolescence and the risk of psychosis: a brief review of the preclinical evidence. Prog Neuropsychopharmacol Biol Psychiatry 2014; 52: 41\u201344.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFmp20174_CR64","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbr.2008.11.039","volume":"204","author":"KY Tseng","year":"2009","unstructured":"Tseng KY, Chambers RA, Lipska BK . The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav Brain Res 2009; 204: 295\u2013305.","journal-title":"Behav Brain Res"},{"key":"BFmp20174_CR65","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nn.3647","volume":"17","author":"E Soria-G\u00f3mez","year":"2014","unstructured":"Soria-G\u00f3mez E, Bellocchio L, Reguero L, Lepousez G, Martin C, Bendahmane M et al. The endocannabinoid system controls food intake via olfactory processes. Nat Neurosci 2014; 17: 407\u2013415.","journal-title":"Nat Neurosci"},{"key":"BFmp20174_CR66","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jsbmb.2015.09.030","volume":"160","author":"M Vall\u00e9e","year":"2015","unstructured":"Vall\u00e9e M . Neurosteroids and potential therapeutics: focus on pregnenolone. J Steroid Biochem Mol Biol 2015; 160: 78\u201387.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"BFmp20174_CR67","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1001\/jamapsychiatry.2014.453","volume":"71","author":"I Mathew","year":"2014","unstructured":"Mathew I, Gardin TM, Tandon N, Eack S, Francis AN, Seidman LJ et al. Medial temporal lobe structures and hippocampal subfields in psychotic disorders: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. JAMA Psychiatry 2014; 71: 769\u2013777.","journal-title":"JAMA Psychiatry"},{"key":"BFmp20174_CR68","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1176\/appi.ajp.2010.09081187","volume":"167","author":"CA Tamminga","year":"2010","unstructured":"Tamminga CA, Stan AD, Wagner AD . The hippocampal formation in schizophrenia. Am J Psychiatry 2010; 167: 1178\u20131193.","journal-title":"Am J Psychiatry"},{"key":"BFmp20174_CR69","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.schres.2014.09.041","volume":"167","author":"S Heckers","year":"2014","unstructured":"Heckers S, Konradi C . GABAergic mechanisms of hippocampal hyperactivity in schizophrenia. Schizophr Res 2014; 167: 4\u201311.","journal-title":"Schizophr Res"},{"key":"BFmp20174_CR70","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/schbul\/sbs062","volume":"38","author":"CA Tamminga","year":"2012","unstructured":"Tamminga CA, Southcott S, Sacco C, Wagner AD, Ghose S . Glutamate dysfunction in hippocampus: relevance of dentate gyrus and CA3 signaling. Schizophr Bull 2012; 38: 927\u2013935.","journal-title":"Schizophr Bull"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/mp20174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/mp20174","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/mp.2017.4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/mp20174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T02:51:09Z","timestamp":1648781469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/mp20174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,21]]},"references-count":70,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["BFmp20174"],"URL":"https:\/\/doi.org\/10.1038\/mp.2017.4","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,21]]},"assertion":[{"value":"31 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PVP and GM are founders, stakeholders and consultants for the start-up company Aelis Farma. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}